Skip to content

Euroimmun Anti-Desmoglein 1 ELISA (IgG), Anti-Desmoglein 3 ELISA (IgG)

by Euroimmun Us, Inc.

510(k) K091969

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 6 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 6 Oct 2026. What this means

Regulatory status

as of registry sync 6 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK091969 Date2 Sep 2010ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 6 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

Full name
Euroimmun Anti-Desmoglein 1 Elisa (Igg), Euroimmun Anti-Desmoglein 3 Elisa (Igg)
510(k) Number
FDA Product Code
NBO
Device Class
Class II
Regulation
21 CFR Part 866.5660
Advisory Committee
Immunology
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Euroimmun Anti-Desmoglein 1 ELISA (IgG) and Anti-Desmoglein 3 ELISA (IgG) are in vitro diagnostic assays classified as autoantibodies targeting skin antigens (desmoglein 1 and desmoglein 3). These enzyme-linked immunosorbent assays detect IgG class autoantibodies in human serum or plasma, aiding in the identification of autoimmune dermatological conditions.

These kits are intended for laboratory use by trained personnel and utilize antigen-coated microplate wells for sample analysis. Supplied as single-use diagnostic reagents, they are regulated under FDA 510(k) clearance (K091969) and fall under Class II medical devices (regulation number 866.5660). No MRI safety or sterility claims are specified in the device data.

Other devices from Euroimmun Us Inc.

See all devices from Euroimmun Us Inc. →

Questions

AI-generated answers, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What autoimmune skin conditions can these ELISA tests help identify, and how do they work?

    These assays detect IgG autoantibodies against desmoglein 1 and desmoglein 3 proteins, which are key components of skin cell adhesion. Elevated levels of these antibodies are linked to autoimmune blistering disorders like pemphigus vulgaris (targeting both desmoglein 1 and 3) and pemphigus foliaceus (targeting desmoglein 1). The tests use enzyme-linked immunosorbent assay (ELISA) technology to measure antibody presence in human serum or plasma by binding to antigen-coated microplate wells, enabling laboratory confirmation of suspected autoimmune dermatological conditions.

  • Are these kits designed for single-use or repeated testing, and how should they be stored?

    The kits are explicitly supplied as single-use diagnostic reagents, meaning each microplate or component is intended for one analysis cycle only. Storage instructions are not detailed in the provided data, but typical ELISA reagents require refrigeration (2–8°C) and protection from light until use. Always refer to the included package insert for precise storage conditions and expiration details.

  • What type of laboratory personnel are qualified to use these assays, and what sample types can they analyze?

    These assays are intended for use by trained laboratory personnel, such as clinical laboratory scientists or technicians with experience in immunology and ELISA techniques. They are designed to analyze human serum or plasma samples, which should be collected and processed according to standard clinical laboratory protocols to ensure accurate antibody detection.

  • How are these devices regulated, and what does the FDA’s 510(k) clearance indicate about their safety and performance?

    These assays are regulated under the FDA’s 510(k) clearance pathway (K091969) and classified as Class II medical devices (regulation number 866.5660). The clearance indicates that Euroimmun demonstrated the devices are substantially equivalent to a legally marketed predicate device in terms of safety and performance. This does not imply approval for specific clinical uses but confirms compliance with FDA requirements for in vitro diagnostic assays targeting autoantibodies in immunology.